Zanxit-M Tablet contains a combination of Flupenthixol (0.5 mg) and Melitracen (10 mg), formulated for the management of depressive and anxiety disorders. Flupenthixol is a typical antipsychotic agent with anxiolytic and mood-stabilizing properties, acting primarily through dopamine receptor antagonism, which helps in alleviating psychomotor agitation and improving mood. Melitracen, a tricyclic antidepressant, exerts its therapeutic effects by inhibiting the reuptake of norepinephrine and serotonin, thereby enhancing neurotransmitter availability in the central nervous system. The synergistic action of these components makes Zanxit-M effective in treating symptoms associated with depression, anxiety, and psychosomatic disorders. It is indicated for patients exhibiting depressive states accompanied by anxiety, agitation, or somatic complaints. Zanxit-M should be administered under medical supervision, with dosage tailored to individual patient needs to minimize adverse effects. Common side effects may include dry mouth, dizziness, sedation, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiovascular disease, glaucoma, or urinary retention. Contraindications include hypersensitivity to the active ingredients and concurrent use of monoamine oxidase inhibitors. Regular monitoring is recommended to assess therapeutic response and detect potential side effects.